Magaly Zappa

TL;DR: Sunitinib showed pronounced toxicities at a dose of 50 mg/day in patients with unresectable HCC and the response rate was low, and the study did not meet the primary endpoint based on RECIST criteria.

TL;DR: In this article, the authors evaluated a therapeutic strategy uniformly applied during the last 8 years in a single referral center, and concluded that excellent survival can be achieved in BCS patients when therapeutic procedures are introduced by order of increasing invasiveness, based on the response to previous therapy rather than on the severity of the patient's condition.

TL;DR: MRI findings significantly associated with surgical pathological inflammation in Crohn's disease are identified and these lesions are considered potentially reversible and may be efficiently treated medically.

TL;DR: A successful response to adalimumab was observed in about two-thirds of CD patients with SSBS and was prolonged in nearly half of them till the end of follow-up, and more than half of the patients were free of surgery 4 years after treatment initiation.

TL;DR: FOLFIRI regimen is a safe and potentially efficient chemotherapy given as second-line in patients with NECs grade 3 who remain in good condition and with correct liver tests after failure of etoposide-platinum combination, and should be confirmed in a future prospective study.